Navigation Links
QPS Announces the Acquisition of Xendo Drug Development
Date:7/26/2010

NEWARK, Del. and GRONINGEN, Netherlands, July 26 /PRNewswire/ -- QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development BV (XDD), headquartered in Groningen, The Netherlands.  XDD, a European contract research organization (CRO), will be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS Holdings, LLC.

(Logo:  http://photos.prnewswire.com/prnh/20100726/PH39912LOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100726/PH39912LOGO )

With the completion of this acquisition, QPS further expands its global range of linearly integrated resources and services:

  • Drug discovery and development from preclinical to clinical studies for IND and NDA regulatory submissions.
  • 300 clinical pharmacology beds on three continents - 24 in the Netherlands, 24 in Taiwan and 240 in the USA - one of the world's largest phase 1 site offerings.
  • Start-up time for phase 1 clinical trials is four to six weeks, compared to several months in other European countries. Moreover, phase 2 can follow phase 1 without interruption.  Many international pharmaceutical and biotech companies have conducted first entry into man (FIM) studies in the Netherlands. This is due to Netherlands' favorable regulatory environment, streamlined protocol approval process and lower cost of managing trials.
  • One of the world's largest capacities in bioanalysis for small molecules and biologics, with global bioanalysis facilities in the USA, Europe and Asia.
  • Complete ADME package for regulatory submissions from preclinical studies to radiolabeled human mass balance (including microdosing) studies.
  • CNS drug research and development, such as Alzheimer therapy, from patient stratification, to the clinic, to in vivo imaging, to PK/PD correlation and efficacy evaluation, with clinical genotyping and specialized biomarker assay capability to support the pursuit of targeted therapies and personalized medicines..  

XDD has state-of-the-art large and small molecule bioanalytical laboratories and a dedicated 24-bed clinical pharmacology unit (CPU) located at University Medical Center Groningen (UMCG).  Established in 2004, this CPU has performed over 100 clinical pharmacology studies - many of them first entry into man (FIM) studies - across all major therapeutic areas.  This location provides comprehensive safety monitoring with 24/7 access to hospital-based crash teams and clinical specialists.  XDD also offers an extensive database of healthy volunteers as well as  special and patient populations.

"Pooling our strengths will enable XDD and QPS to serve our clients even better.  Our leading capability in conducting high quality bioanalysis and phase 1 studies, combined with our well established expertise in ADME, genotyping and drug development process will make QPS an ideal drug development partner for our pharmaceutical and biotech clients worldwide," said Ben Chien, Chairman, and CEO of QPS holdings.

"Joining the QPS organization enables XDD to realize its ambitions for global growth.  In terms of activities, size and location, QPS and XDD are a perfect fit. Our combined operations in Asia, Europe and the US position us ideally to expand our portfolios in the increasingly consolidated pharmaceutical and biotechnology sector, our primary market," said Koos Koops, XDD's former chief executive officer. Koops will head the XDD -QPS Netherlands division of QPS.

"As both QPS and XDD facilities share the same high standards and customer service philosophy, this merger will further strengthen our ability to provide our clients with quality, services, and competitive pricing worldwide," stated Ben Chien.

About Xendo

Established in 1999, XDD is a European CRO with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients.  XDD employs over 100 people, and provides early & late phase clinical development, data management, biometrics, medical writing, bioanalysis and resourcing solutions services.  Further information is available at www.xendo.com

About QPS

Founded in 1995, QPS (www.qps-usa.com) has bioanalysis and DMPK facilities at its Newark, DE, USA headquarters, a laboratory in Taipei, Taiwan, and phase 1 facility in Springfield, Missouri.  QPS has been providing quality services in regulated and non-regulated bioanalysis (LC/MS/MS, immunoanalytical, and hybridization-ELISA), DMPK, protein biomarkers, pharmacogenomics and pharmacogenetics markers, and phase 1 studies to its clients worldwide.


'/>"/>
SOURCE QPS
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... The key factors driving the growth of dialysis ... growth and increasing healthcare expenditure. Some of the noteworthy trends ... ESRD patients, rising demand for home PD treatment and huge ... market is hindered by high treatment costs and stringent regulations. ... Complete ...
(Date:3/23/2017)... INDIANAPOLIS , March 23, 2017  Eli ... the William Sansum Diabetes Center have established a research ... by diabetes through enhanced research, education and care. ... disease bears a disproportionate weight on Latino families in ... David Kerr , M.D., FRCPE, director of Innovation and ...
(Date:3/23/2017)... March 23, 2017   BioSpace , the leading ... partnered with Indiana Biosciences Research Institute and ... and educational institutions to bring the state,s life sciences ... Hotbed map, an artistic representation of the region,s booming ... to Vice President Mike Pence , a long-time ...
Breaking Medicine Technology:
(Date:3/23/2017)... York, NY (PRWEB) , ... March 23, 2017 , ... 82% of adults are unaware ... 3 kids do not brush their teeth the minimum two times a day that dentists ... with students missing 51 million hours of school and adults missing 164 million hours of ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced today ... accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary ... have excellent programs for the delivery and improvement of disease management and that ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... and businesses of the greater Fort Collins area, has unveiled a collaboration with ... community involvement program. Donations to this worthy cause may now be made at ...
(Date:3/23/2017)... ... , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: , ... , 43rd President of the United States of America: George W. Bush , ... Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural ... all aspects of people’s health and nutrition, announced its product Leyzene is now ... Natural Subsistence develops nutritional supplements that help people improve all aspects of their ...
Breaking Medicine News(10 mins):